Darifenacin is a urinary antispasmodic drug developed by the U.S. Food And Drug Administration and initially approved for treating the symptoms of overactive bladder (OAB).

Darifenacin is used to treat the symptoms of overactive bladder (OAB). It is a medical condition caused by a sudden, frequent, and uncontrollable urge to urinate, often accompanied by urinary frequency (urinating more often than usual) and urinary urgency (a strong and immediate need to urinate). Individuals with OAB may experience these symptoms even when the bladder is not full, leading to a sense of urgency that can be difficult to control.

Take the Darifenacin as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the capsule if your doctor advises you to stop.

The side effects known to occur commonly during the treatment with Darifenacin are headache, stomach pain, indigestion, sickness, dry eyes, nasal dryness, dry mouth, constipation, urinary tract infection, nausea, flu-like illness, and accidental injury.

This drug is contraindicated in individuals with known hypersensitivity or allergy to it or its component. Individuals with certain medical conditions, such as ulcerative colitis, myasthenia gravis, narrow-angle glaucoma, severe liver disease, or urinary retention, should avoid consuming Darifenacin.. 

It's important to provide your doctor with a complete medical history to determine if the medication is suitable for you. Also, this drug is not recommended during pregnancy and should be taken cautiously while breastfeeding. Grapefruit juice may interact with this medicine and affect its absorption. It's recommended to avoid grapefruit juice while taking this medication.

Darifenacin can cause dizziness or blurred vision in some individuals. If you experience these effects, avoid activities that require mental alertness or clear vision until you know how the medication affects you.

1. Merus Labs Luxco II S.à R.L, Electronic Medicines Compendium (EMC), [Revised on Nov 2020] [Accessed on 25th August 2023], https://www.medicines.org.uk/emc/files/pil.5129.pdf
2. Novartis Pharma Stein AG, US Food & Drug Administration, [Revised on Mar 2012] [Accessed on 25th August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf
3. KD Tripathi, Anticholinergic Drugs and Drugs Acting on Autonomic Ganglia, Essentials of Medical Pharmacology, 8th Edition, 2019,.124-135.
4. J. Goddard, A.N. Turner, Kidney and urinary tract disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 461-523.

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.